Royalty Report: Drugs, Disease, Therapeutic – Collection: 278002

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Diagnostic
  • Respiratory
  • Delivery
  • Fibrosis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 278002

License Grant
The agreement is for Phase 2b Clinical Trial for lenabasum, and commercialization.
License Property
Lenabasum is an oral anti-inflammatory drug in adults with cystic fibrosis.
Field of Use
The field of use is for patients with cystic fibrosis.  Licensee is a clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

IPSCIO Record ID: 256262

License Grant
The Licensors grant an exclusive license in the Territory under the Licensed Patents and Information for all  purposes, including without limitation, to develop, use, make, have made, import, have imported, export, have exported, offer for sale, have sold and sell Licensed Products.
License Property
The patents are for anti-fibrotic uses of Pirfenidon.  

'Licensed Patents' means that certain U.S. Patent No. 5,310,562 with respect to the anti-fibrotic uses of Pirfenidon.

Field of Use
The field of use is for the therapeutic treatment of a specific fibrotic human disease.
The Licensee licensed the rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis.
Fibrosis, or the accumulation of extracellular matrix molecules that make up scar tissue, is a common feature of chronic tissue injury. Pulmonary fibrosis, renal fibrosis, and hepatic cirrhosis are among the more common fibrotic diseases, which in aggregate represent a huge unmet clinical need.

IPSCIO Record ID: 26673

License Grant
The University grants to the Licensee and exclusive, worldwide License with the right to grant sublicenses, in all fields of use, to make, have made, import, use, market, offer for sale, and sell Licensed Products and to practice Licensed Processes.

Pursuant to this Agreement, we will use our best efforts to commercialize COPREXATM for the therapeutic uses embodied in the issued patent and pending patent application.

COPREXATM has been designated by the FDA as an orphan drug for the treatment of Wilson’s disease patients presenting with neurologic complications.

License Property
Licensed Products means any products comprises or all uses of U.S. Patent No. 6,855,340, corresponding international applications, and a related corresponding patent application that relates to various uses of anticopper therapeutics, including COPREXATM, to treat inflammatory and fibrotic diseases.

Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This is as opposed to formation of fibrous tissue as a normal constituent of an organ or tissue. Scarring is confluent fibrosis that obliterates the architecture of the underlying organ or tissue.

Field of Use
COPREXATM is an oral, small-molecule, anti-copper agent that is highly specific for lowering the level of free copper in serum, the most toxic form of copper in the body. Thus, it may be suited for the treatment of central nervous system (CNS) diseases in which abnormal serum and CNS copper homeostasis are implicated.

IPSCIO Record ID: 29059

License Grant
The Licensee executed an amendment to its award Agreement with the Licensor, to support early clinical evaluation of Lomucin involving subjects with cystic fibrosis.

IPSCIO Record ID: 383576

License Grant
Licensors, one being a University, grant a non-exclusive license under the Licensed Patents and Technology to make, have made, use, including use in the performance of services for, by or on behalf of its customers, have used, import, market and/or sell, in the Territory, Products designed and marketed solely for use in the Field of Use.

Licensee agrees to mark, and to require Affiliates to mark, Products with the appropriate patent notice as approved by Licensors, when appropriate.

License Property
The University Licensor and the Research Institute of the Hospital for Sick Children of Toronto, Ontario, Canada, have conducted research relating to cystic fibrosis.

Technology shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensors, covering the gene for cystic fibrosis and uses thereof as covered by the claims of U.S. Patents entitled Cystic Fibrosis Gene.

Field of Use
The Field of Use shall refer to the field for which Product(s) may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Product(s) to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.

IPSCIO Record ID: 67284

License Grant
The company entered into a global collaboration agreement focused on the discovery and worldwide development and commercialization of potentiator and corrector molecules in a potential triple combination therapy for the treatment of CF (Cystic Fibrosis).
License Property
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide and approximately 30,000 patients in the United States.  CF is a chronic disease that affects the lungs and digestive system.  CF patients, with significantly impaired quality of life, have an average lifespan approximately 50% shorter than the population average, with the median age of death at 40.  There currently is no cure for CF.  CF patients require lifelong treatment with multiple daily medications, frequent hospitalizations and ultimately lung transplant, which is life-extending but not curative.  CF is caused by a mutation in the gene for the CFTR protein, which results in abnormal transport of chloride across cell membranes.  Transport of chloride is required for effective hydration of epithelial surfaces in many organs of the body.  Normal CFTR channel moves chloride ions to outside of the cell.  Mutant CFTR channel does not move chloride ions, causing sticky mucous to build up on the outside of the cell.  CFTR dysfunction results in dehydration of dependent epithelial surfaces, leading to damage of the affected tissues and subsequent disease, such as lung disease, malabsorption in the intestinal tract and pancreatic insufficiency.
Field of Use
This agreement pertains to the drug industry for the treatment of cystic fibrosis.

IPSCIO Record ID: 273401

License Grant
Licensor, a non-profit organization, grants a worldwide, non-exclusive license, without the right to sublicense, to the Licensor Background Intellectual Property, and such Intellectual Property as may be conceived, developed or acquired by Licensor, for all uses and purposes by Licensee related to the Research Program and Research Plan and that may be necessary or useful for the development or exploitation of a Drug Product.

Licensee and/or its licensees and sublicensees shall have exclusive rights to manufacture, market, sell and distribute all Drug Products in the Territory.

License Property
Licensee shall use Licensor s Data Safety Monitoring Board and the Therapeutics Development Network (TDN), as feasible, in connection with its clinical trials involving cystic fibrosis (CF) patients.

Drug Product resulting from a Drug Product Candidate shall mean a finished dosage form which is approved by a regulatory authority for administration to patients as a pharmaceutical.

Field of Use
The Field shall mean the treatment of conditions or diseases in the cystic fibrosis field, asthma, chronic bronchitis and chronic obstructive pulmonary disease.

IPSCIO Record ID: 263060

License Grant
In this Agreement, the Licensee expanded the scope of the license agreement with the Licensor, who prior to 2015 was Parent of Licensee, for rights to develop and commercialize pulsed nitric oxide for idiopathic pulmonary fibrosis to include patients with Pulmonary Fibrosis (PH-PF).
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices, based on proprietary pulsatile nitric oxide delivery.

INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.

Field of Use
The clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases,  expanded the scope of the license from PH-IPF to PH in patients with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung disease, with a royalty on net sales of any commercial products for PH-PF.  Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.